BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19661026)

  • 21. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Bang YJ; Van Cutsem E; Feyereislova A; Chung HC; Shen L; Sawaki A; Lordick F; Ohtsu A; Omuro Y; Satoh T; Aprile G; Kulikov E; Hill J; Lehle M; Rüschoff J; Kang YK;
    Lancet; 2010 Aug; 376(9742):687-97. PubMed ID: 20728210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Docetaxel-based chemotherapy in the treatment of gastric cancer.
    Roth AD; Ajani J
    Ann Oncol; 2003; 14 Suppl 2():ii41-4. PubMed ID: 12810457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A case of advanced gastric cancer successfully treated with trastuzumab, capecitabine, and Cisplatin therapy followed by curative resection].
    Kato S; Asao Y; Aisu Y; Honda K; Ando Y; Nishino H; Nishiuchi A; Kadokawa Y; Machimoto T; Furuyama H; Yoshimura T
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2311-3. PubMed ID: 25731506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A recent trial of chemo-radiation with S-1 against gastric cancer].
    Saikawa Y; Kiyota T; Nakamura R; Wada N; Yoshida M; Kubota T; Kumai K; Shigematsu N; Kubo A; Kitajima M
    Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():99-105. PubMed ID: 16897982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic treatment of gastric cancer.
    Dickson JL; Cunningham D
    Eur J Gastroenterol Hepatol; 2004 Mar; 16(3):255-63. PubMed ID: 15195888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging role of capecitabine in gastric cancer.
    Comella P; Franco L; Casaretti R; de Portu S; Menditto E
    Pharmacotherapy; 2009 Mar; 29(3):318-30. PubMed ID: 19249950
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3).
    Seo S; Ryu MH; Park YS; Ahn JY; Park Y; Park SR; Ryoo BY; Lee GH; Jung HY; Kang YK
    Gastric Cancer; 2019 May; 22(3):527-535. PubMed ID: 30386954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Capecitabine for the treatment of gastric cancer.
    Kim TY; Oh DY; Bang YJ
    Expert Rev Gastroenterol Hepatol; 2015; 9(12):1471-81. PubMed ID: 26470733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [HER2 and gastric cancer: a novel therapeutic target for trastuzumab].
    Bouché O; Penault-Llorca F
    Bull Cancer; 2010 Dec; 97(12):1429-40. PubMed ID: 21134821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant and neoadjuvant therapy for gastric cancer.
    Kelsen DP
    Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.
    Fazio N; Biffi R; Maibach R; Hayoz S; Thierstein S; Brauchli P; Bernhard J; Stupp R; Andreoni B; Renne G; Crosta C; Morant R; Chiappa A; Luca F; Zampino MG; Huber O; Goldhirsch A; de Braud F; Roth AD; ;
    Ann Oncol; 2016 Apr; 27(4):668-73. PubMed ID: 26712905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T).
    Weissinger F; Reymond M; Dumke K; Krüger M
    Onkologie; 2011; 34(10):548-51. PubMed ID: 21985855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Efficacy of oxaliplatin plus 5-fluorouracil/leucovorin calcium combined with concurrent radiotherapy for local advanced gastric cancer].
    Shao ZY; Zhang JD
    Zhonghua Yi Xue Za Zhi; 2008 Sep; 88(36):2547-9. PubMed ID: 19080647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial.
    Rivera F; Romero C; Jimenez-Fonseca P; Izquierdo-Manuel M; Salud A; Martínez E; Jorge M; Arrazubi V; Méndez JC; García-Alfonso P; Reboredo M; Barriuso J; Muñoz-Unceta N; Jimeno R; López C
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1175-1181. PubMed ID: 30927036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BAK is a predictive and prognostic biomarker for the therapeutic effect of docetaxel treatment in patients with advanced gastric cancer.
    Kubo T; Kawano Y; Himuro N; Sugita S; Sato Y; Ishikawa K; Takada K; Murase K; Miyanishi K; Sato T; Takimoto R; Kobune M; Nobuoka T; Hirata K; Takayama T; Mori M; Hasegawa T; Kato J
    Gastric Cancer; 2016 Jul; 19(3):827-38. PubMed ID: 26486506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Postoperative chemoradiotherapy in gastric cancer--a phase I-II study of radiotherapy with dose escalation of weekly cisplatin and daily capecitabine chemotherapy.
    Jansen EPM; Boot H; Dubbelman R; Verheij M; Cats A
    Ann Oncol; 2010 Mar; 21(3):530-534. PubMed ID: 19690058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer.
    Garrido M; Fonseca PJ; Vieitez JM; Frunza M; Lacave AJ
    Expert Rev Anticancer Ther; 2014 Aug; 14(8):887-900. PubMed ID: 24953238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801).
    Stahl M; Maderer A; Lordick F; Mihaljevic AL; Kanzler S; Hoehler T; Thuss-Patience P; Mönig S; Kunzmann V; Schroll S; Sandermann A; Tannapfel A; Meyer HJ; Schuhmacher C; Wilke H; Moehler M;
    Eur J Cancer; 2018 Apr; 93():119-126. PubMed ID: 29501977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
    Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L
    Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of chemotherapy in unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction.
    Bozkurt M; Amlashi FG; Blum Murphy M
    Minerva Chir; 2017 Aug; 72(4):317-333. PubMed ID: 28415835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.